



Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

April 27, 2018

CAMBRIDGE, Mass., April 26, 2018 – [Gamida Cell](#), a leading cellular and immune therapeutics company, today announced the appointments of Josh Hamermesh as chief business officer and Paul Nee as vice president, marketing.

Mr. Hamermesh will lead the business operations and corporate development strategies for the company. Mr. Hamermesh joins Gamida Cell from Locust Walk Partners, Inc., a strategic partnering and financing transaction advisory firm, where he served as senior vice president. At Locust Walk, Mr. Hamermesh played an instrumental role in leading numerous transactions across an array of therapeutic areas and technologies. Mr. Hamermesh previously served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company's in-licensing, out-licensing and alliance management activities.

Mr. Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at Gamida Cell. He joins from Sunovion Pharmaceuticals, where he was responsible for commercial forecasting initiatives across various corporate functions in his role as senior director of forecasting. Prior to that, he served in financial and commercial operations roles of increasing responsibility at large and small biopharmaceutical companies including Biogen, AMAG Pharmaceuticals, Amgen and Novartis.

"We are pleased to welcome Josh and Paul to the Gamida Cell leadership team," said Julian Adams, Ph.D., chairman and chief executive officer of Gamida Cell. "Their combined experience in corporate strategy, business development and commercialization will be invaluable to Gamida Cell's continued growth as we advance our clinical programs in blood cancers and rare genetic diseases."

About Gamida Cell

Gamida Cell is a leader in cellular and immune therapeutics, dedicated to treating patients with cancer and rare genetic diseases. The company is building a diverse pipeline based on its proprietary NAM technology platform to deliver transformative medicines to patients in need of new treatment options. To learn more about Gamida Cell, including current clinical studies, please visit [gamida-cell.com](#) and on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Contact:

Katie Engleman
Pure Communications
katie@purecommunications.com
+1 910.509.3977

Investor Contact:

Daniel Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
+1 617.535.7746